What this means
In a randomized trial of 96 people, berberine plus surgery healed more ulcers than surgery alone. The authors say the link to the PDGF-B pathway needs more study, and larger trials are needed.
Plain-English summary written by an AI model from the abstract. The original is below.
- Who it was tested in
- 96 adults with diabetic foot ulcers, plus small groups for cell studies
- Kind of research
- A clinical trial in people
The science
- Original title
- Berberine improves diabetic foot ulcer healing after tibial transverse osteotomy by inhibiting the PDGF-B/PDGFRβ signaling pathway.
- Authors
- Zhang R, Jiang H
- Journal
- Pakistan journal of pharmaceutical sciences
- Published
- Oct 24, 2026
- Study type
- Clinical trial · in humans
- PMID
- 42924998 ↗
Abstract
Background
Tibial transverse osteotomy (TTO) is a promising but limited surgical option for diabetic foot (DF). Berberine, a natural compound from Coptis chinensis, exhibits anti-inflammatory and pro-angiogenic effects relevant to metabolic diseases. This study aimed to evaluate whether adjunctive berberine enhances the therapeutic outcomes of TTO in DF patients and to explore its potential association with the platelet-derived growth factor-B (PDGF-B)/PDGF receptor-β (PDGFRβ) signaling pathway.
What they did
This was a prospective, single-center, randomized, placebo-controlled, parallel-group, blinded trial. Of 200 screened DF patients, 96 eligible participants (Wagner grade 2-4) scheduled for TTO were randomized 1:1 to receive either TTO plus local berberine injections (n=48) or TTO plus local saline placebo (n=48). An additional non-randomized diabetic reference group (n=10) and healthy control group (n=10) were included for exploratory cellular studies only. The primary outcome was the total effective rate of ulcer healing at 3 months. Secondary outcomes included changes in Ankle-Brachial Index (ABI), ulcer area, Visual Analogue Scale (VAS) pain score and serum inflammatory markers (hs-CRP, IL-6). Exploratory outcomes comprised serum VEGF, bFGF and PDGF-B levels, as well as fibroblast apoptosis in wound tissue.
What they found
All 96 randomized participants completed the 3-month follow-up, with no dropouts. The berberine group demonstrated a significantly higher total effective rate than the surgery-alone group (87.5% vs. 68.8%; risk difference, 18.7%; 95% CI, 1.2% to 36.2%; P < 0.05). At 3 months, the berberine group also showed greater improvements in ABI (mean difference, 0.13; 95% CI, 0.08 to 0.18; P < 0.01) and ulcer healing rate (mean difference, 16.7%; 95% CI, 9.5% to 23.9%; P < 0.01), along with more significant reductions in hs-CRP and IL-6. Berberine treatment was associated with reduced fibroblast apoptosis in wound tissue (mean difference, -1.10%; 95% CI, -1.56% to -0.64%; P = 0.001) and lower protein expression of PDGF-B and PDGFRβ. No severe adverse events related to berberine injections were reported. In DF patients undergoing TTO, adjunctive local berberine therapy significantly improves the total effective rate and promotes ulcer healing, with benefits associated with reduced inflammation and fibroblast apoptosis and downregulation of the PDGF-B/PDGFRβ pathway. These findings are correlative and require further mechanistic validation. Larger multi-center trials are needed to confirm efficacy and safety.
The authors' abstract, grouped under plain headings from its own section labels.
Zhang R, Jiang H Berberine improves diabetic foot ulcer healing after tibial transverse osteotomy by inhibiting the PDGF-B/PDGFRβ signaling pathway. Pakistan journal of pharmaceutical sciences. 2026. doi:10.36721/PJPS/2026.40.15603.1. PMID: 42924998. https://pubmed.ncbi.nlm.nih.gov/42924998/
See all research on Berberine →